HROW · investment memo
Roughly what management's own FY2026 guidance implies on a GAAP basis. Sits ABOVE the 7.3% TTM realised operating margin, i.e. it credits the guided operating leverage in full.
Four distinct questions, one field each. A price is not a thesis: the trigger below forces a re-underwrite and freezes further purchases — it is never an automatic sell.
A daily close below $32.23 triggers a mandatory re-underwrite and freezes further purchases. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.
Not stated. This name has no falsifiable invalidation conditions on file, so it cannot be risk-monitored. That is a gap in the research, not a clean bill of health — recorded rather than hidden.
Named cause: the IHEEZO Medicare reimbursement reset compounding with an inflexible fixed charge. Not a volatility figure. The mechanism: IHEEZO was 30% of FY2025 revenue. Its ASC pass-through expired 2026-03-31; Q1-2026 IHEEZO revenue was $1.85m against $35.88m in Q4-2025. Management's stated remedy is that the in-office retina channel "fully offsets" the lost ASC volume this year — an assertion with no realised quarter behind it. Simultaneously the compounding segment is −32.7% YoY with California's 503B and 503A out-of-state licences surrendered in January 2026. If both continue, FY2026 rev